Varmora Granito's ₹1,096.04 crore initial public offering (IPO) entered its second day of public subscription today, September 23, 2026, with a price band of ₹140 to ₹148 per share. As of 10:05 A.M on the second day of bidding, the issue had been subscribed 0.12 times.
The IPO will remain open until September 24, 2026. The basis of allotment is expected to be finalised on September 25, 2026, and the shares are tentatively scheduled to be listed on the BSE and NSE on September 29, 2026.
The expected IPO schedule is as follows:
|
Event |
Date |
|
Subscription Opening Date |
22 September 2026 |
|
Subscription Closing Date |
24 September 2026 |
|
Basis of Allotment Date |
25 September 2026 |
|
Refund Initiation Date |
28 September 2026 |
|
Credit of Shares |
28 September 2026 |
|
Listing on BSE and NSE |
29 September 2026 |
Note: The allotment and listing dates are tentative and may be revised.
Explore other Upcoming IPOs on BSE and NSE.
[September 23, 2026, 10:05 A.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
0.00x |
|
Non-Institutional Investors (NIIs) |
0.05x |
|
Retail Individual Investors (RIIs) |
0.22x |
|
Total |
0.12x |
The company intends to utilise the net proceeds from the fresh issue towards:
Incorporated in 2003, Varmora Granito Limited manufactures ceramic and vitrified tiles, with glazed vitrified tiles (GVT) being its largest revenue contributor.
The company operates nine manufacturing facilities in Morbi, Gujarat, and generated 78.55% of its FY2025 revenue from in-house manufactured products. As of March 31, 2025, it had a distribution network of 286 exclusive brand outlets and 2,000+ multi-brand outlets across India and overseas markets.
|
Particulars |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
|
Revenue from operations |
1,446.03 |
1,435.48 |
1,334.95 |
|
EBITDA |
198.29 |
150.33 |
180.68 |
|
Profit After Tax (PAT) |
30.77 |
44.94 |
55.06 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here